Clinical Trial Update: Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update describing the addition of iberdomide to therapy for neuroblastoma that has recurred or is refractory, in Phase 1/2 and not yet recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ganglioneuroblastoma
• Neuroblastoma

Drugs mentioned

• iberdomide (iberdomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING